[ Diabetes Type 2 ]

Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. – PubMed


A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs — Eylea, Avastin and Lucentis — used to treat diabetic macular edema are all effective. Intraocular tamponade with perfluoropropane gas has been hypothesized to either tamponade the retinal vasculature or stimulate clot formation. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. Reinjection was performed in three eyes 4–6 months after the first injection. There are two types of macular degeneration: dry and wet. Laser therapy, the current standard of care, has provided stabilization of vision in many… Andrew J.

Early (4-6 weeks) rebleed rates were 15% versus 13% in the bevacizumab and untreated groups, respectively, and not statistically different. Intravitreal bevacizumab might primarily affect blood vessels, and the effects on pericytes and myofibroblasts might be secondary. Intravitreal injection of 1.25 mg bevacizumab given at the end of vitrectomy appears safe and effective for reducing the incidence of recurrent postoperative vitreous hemorrhage after diabetic vitrectomy. Early diagnosis of DR is possible only with strict screening protocols. Chemically, Lucentis and Avastin are very similar. This approach is potentially useful in allowing (within a planned temporal window) a safe and efficient PRP to be performed while minimizing the risk of its complications.

Tags: , ,